With an estimated 5 million Americans battling opioid use disorder—resulting in tens of thousands of deaths each year—a new study by The University of Texas at Arlington examines how updated Centers for Disease Control and Prevention guidelines can help nurse practitioners reduce misuse and protect patients.

The world’s first academic review into bamboo consumption has identified a surprising range of health benefits, including helping control blood sugar, fighting inflammation, improving gut health and acting as an antioxidant.

The review, which involved researchers from Anglia Ruskin University (ARU) in England, is the first to collate and analyse all published research into the consumption of bamboo, which is the fastest growing plant on earth.

Cambridge, Massachusetts, January 14, 2025 - Insilico Medicine (“Insilico”, HKEX:03696), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the demonstration of its Nach01 multimodal foundation model deployed on Microsoft Discovery, Microsoft’s science-focused platform designed to accelerate research and development through agentic AI. This collaboration highlights Microsoft Discovery’s extensibility with third-party AI models and illustrates how R&D organizations can adopt unified, AI-native workflows for computational drug discovery. By orchestrating secure, multi-step investigations within a Microsoft Azure-native environment, the demonstration underscores key benefits—including enhanced transparency, improved reproducibility, and scalable deployment—empowering scientific teams to streamline and advance discovery processes with great assurance.    

Alcohol use is widespread and alcohol use disorder (AUD) causes substantial harm. AUD affects 29 million individuals and causes more than 140,000 deaths annually in the U.S. alone. Individuals with AUD also often struggle with cognitive deficits, particularly in memory, attention, and cognitive flexibility, which can further undermine recovery. Current drug options are limited, and only modestly effective, so more efficacious and better-tolerated options are urgently needed.

Researchers at Boston University Chobanian & Avedisian School of Medicine report for the first time that guanfacine, a selective alpha-2 adrenergic drug already used clinically for ADHD, reduces heavy alcohol consumption and improve certain alcohol-related cognitive deficits in an experimental model, without the sedation and dangerous drops in body temperature seen with older alpha-2 drugs such as clonidine.